Fig. 3.
Graph showing the incidence of infections. No clinical safety concerns were observed in the cyclosporine-treated patients. The incidence of infectious complications did not differ between dosing groups or between cyclosporine-treated patients and placebo controls. UTI = urinary tract infection.